Hepatocellular Carcinoma

Localized
- No Prior Therapy
  - 1st Line
    - IRB #2377: A humanitarian device exemption use protocol of TheraSphere for treatment of unresectable Hepatocellular Carcinoma
    - IRB #15816: New study to be available soon.
    - IRB #18436: New study to be available soon

Prior Therapy
- 2nd line
  - IRB #17603: Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma
  - No Trials Currently Available

Cholangiocarcinoma

1st Line
- IRB #16033: New study to be available soon

1" or 2"nd Line
- IRB #16255: INCB 54828-202: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

No Trials Currently Available

http://www.ohsu.edu/research/rda/so/knight.php